GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its […]

GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its […]
NICHI BRITE (AFO-202), one of the NICHI GLUCAN brand products for overseas markets, has undergone clinical tri […]
Manuscript published in Stem Cell Reviews and Reports
Technology transfer on cell therapy to Vietnam by GN Corporation leads to new opportunities
Webiner on Cell Therapy Approaches for Urethral Stricture is held on 16 OCt 2022
A look at the potential of beta-glucan for the growing number of non-alcoholic fatty liver diseases
GNC’s activities are introduced in the Japan Cabinet Office’s site ‘Invest Japan’
This is the research on the potential of beta-glucan for autism
A breakthrough achievement on miRNA140 is published in Medicine Innovates
An interview was published in a feature story in Bloomburg